Filtered By:
Therapy: Endocrine Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 38 results found since Jan 2013.

Abstract 2435: FGFR1 is associated with resistance to interaction with estrogen receptor (ER) {alpha} endocrine therapy in ER+/FGFR1-amplified breast cancer
Conclusions: These data suggest FGFR1 binds ER and regulates ligand-independent ER transcriptional activity. This role depends on the FGFR1 kinase activity and may involve its association with cyclin D1. These interactions may explain the endocrine resistance reported in ER+/FGFR1 amplified breast cancers and suggest these tumors should be treated with a combination of antiestrogen and FGFR inhibitors.Citation Format: Luigi Formisano, Christian D. Young, Neil Bhola, Jennifer M. Giltnane, Monica V. Estrada, Carlos L. Arteaga. FGFR1 is associated with resistance to interaction with estrogen receptor (ER) α endocrine therapy...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Formisano, L., Young, C. D., Bhola, N., Giltnane, J. M., Estrada, M. V., Arteaga, C. L. Tags: Clinical Research (Excluding Clinical Trials) Source Type: research

Abstract S3-03: Nuclear FGFR1 interaction with estrogen receptor (ER) {alpha} is associated with resistance to endocrine therapy in ER+/FGFR1-amplified breast cancer
Conclusions: These data support a critical role of ER and FGFR1 interaction in endocrine resistance in ER+/FGFR1-amplified breast cancer. Targeting of FGFR1 in combination with antiestrogens may abrogate resistance to endocrine therapy in these tumors and is worthy of clinical investigation.Citation Format: Formisano L, Young CD, Bhola NE, Bulen B, Estrada VM, Wagle N, Van Allen E, Red Brewer ML, Jansen VM, Guerrero AL, Giltnane JM, Strcker T, Arteaga CL. Nuclear FGFR1 interaction with estrogen receptor (ER) α is associated with resistance to endocrine therapy in ER+/FGFR1-amplified breast cancer. [abstract]. In: Proceedi...
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Formisano, L., Young, C., Bhola, N., Bulen, B., Estrada, V., Wagle, N., Van Allen, E., Red Brewer, M., Jansen, V., Guerrero, A., Giltnane, J., Strcker, T., Arteaga, C. Tags: General Session Abstracts Source Type: research

Knockdown of YAP/TAZ sensitizes tamoxifen-resistant MCF7 breast cancer cells
In conclusion, targeting the YAP/TAZ-PSAT1 axis could sensitize tamoxifen-resistant MCF7 breast cancer cells by modulating the mTORC1-survivin axis.PMID:35231654 | DOI:10.1016/j.bbrc.2022.02.083
Source: Cell Research - March 1, 2022 Category: Cytology Authors: Yu Jin Kim Se-Kyeong Jang Sung-Eun Hong Chan Sub Park Min-Ki Seong Hyun-Ah Kim Ki Soo Park Chun-Ho Kim In-Chul Park Hyeon-Ok Jin Source Type: research

Role of EGF/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells.
Authors: Kavarthapu R, Dufau ML Abstract Prolactin receptor (PRLR) and epidermal growth factor receptor (EGFR/ERBB1) have important roles in the physiology of the human breast and in the etiology and progression of breast cancer. Our present studies in MCF-7 cells revealed that EGF induces up-regulation of PRLR via activation of EGFR signalling pathways leading to activation of estrogen receptor α (ERα). EGF treatment of MCF-7 cells cultured in absence of estradiol induced expression of PRLR that was consistent with the activation of PRLR generic promoter (hPIII). These were abolished by ERα antagonist and siRNA...
Source: Oncotarget - August 27, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Abstract P1-08-03: Identification and characterization of a novel endoxifen substrate, PKC{beta}1, and its interaction with the estrogen receptor
Conclusions: Our findings demonstrated that endoxifen binds and inhibits PKCβ1 at relevant concentrations achieved in the endoxifen clinical trial studies. PKCβ1 interacts with cytoplasmic ERα and PKCβ1 knockdown inhibits cell proliferation and enhances ERα turnover. However, in PKCβ1 overexpressing cells, PKCβ1 may exhibit tumor suppressive effects. These data suggest a complex interaction between PKCβ1 and ERα and that endoxifen's effects on PKCβ1 may alter drug response of endocrine therapy. Further studies are ongoing to characterize the role of PKCβ1 and its role in ER biology and response to endoxifen.Cita...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: C Guo, MJ Kuffel, RA Kudgus, Z Huang, AM Bode, J Cheng, VJ Suman, JM Reid, ES Bruinsma, M Subramaniam, MM Ames, JR Hawse, MP Goetz Tags: Poster Session Abstracts Source Type: research

Abstract P4-10-02: Transmembrane protein 33 (TMEM33) induces apoptosis via UPR signaling and autophagy in breast cancer cells
Conclusions: Our findings demonstrated that endoxifen binds and inhibits PKCβ1 at relevant concentrations achieved in the endoxifen clinical trial studies. PKCβ1 interacts with cytoplasmic ERα and PKCβ1 knockdown inhibits cell proliferation and enhances ERα turnover. However, in PKCβ1 overexpressing cells, PKCβ1 may exhibit tumor suppressive effects. These data suggest a complex interaction between PKCβ1 and ERα and that endoxifen's effects on PKCβ1 may alter drug response of endocrine therapy. Further studies are ongoing to characterize the role of PKCβ1 and its role in ER biology and response to endoxifen.Cita...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: R Clarke, R Hu, X Zhang, L Hilakivi-Clarke, U Kasid Tags: Poster Session Abstracts Source Type: research

GSE106695 GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer
Series Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe estrogen receptor (ER) is expressed in the majority of luminal breast cancers and inhibition of its transcriptional activity with selective estrogen receptor modulators, selective estrogen receptor degraders and/or aromatase inhibitors is a standard approach used in the management of this disease. Despite the positive clinical impact of these interventions, de novo and acquired resistance limits the therapeutic lifespan of these classes of drugs. Considering what is known about the complex mechanisms that contribute to the developmen...
Source: GEO: Gene Expression Omnibus - November 20, 2017 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

GSE106694 GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer (RNA-Seq data set 2)
Contributors : Jeff S Jasper ; Kimberly J Cocce ; Logan Everett ; Suzanne Wardell ; Thomas Westerling ; Taylor Krebs ; Robert Baldi ; Tricia M Wright ; Alex Yllanes ; Jeremy T Blitzer ; Craig Logsdon ; Daniel Rakiec ; David Ruddy ; Terry Hyslop ; Allison Hall ; Jeffrey R Marks ; Gregory E Crawford ; Myles Brown ; Donald P McdonnellSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe estrogen receptor (ER) is expressed in the majority of luminal breast cancers and inhibition of its transcriptional activity with selective estrogen receptor modulators, selective estrogen receptor degrader...
Source: GEO: Gene Expression Omnibus - November 20, 2017 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

GSE106681 GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer (RNA-Seq data set 1)
Contributors : Jeff S Jasper ; Kimberly J Cocce ; Logan Everett ; Suzanne Wardell ; Thomas Westerling ; Taylor Krebs ; Robert Baldi ; Tricia M Wright ; Alex Yllanes ; Jeremy T Blitzer ; Craig Logsdon ; Daniel Rakiec ; David Ruddy ; Terry Hyslop ; Allison Hall ; Jeffrey R Marks ; Gregory E Crawford ; Myles Brown ; Donald P McdonnellSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe estrogen receptor (ER) is expressed in the majority of luminal breast cancers and inhibition of its transcriptional activity with selective estrogen receptor modulators, selective estrogen receptor degrader...
Source: GEO: Gene Expression Omnibus - November 20, 2017 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

GSE108167 GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer DNase hypersensitivity
Contributors : Jeff S Jasper ; Kimberly J Cocce ; Logan Everett ; Suzanne Wardell ; Thomas Westerling ; Taylor Krebs ; Robert Baldi ; Tricia M Wright ; Alex Yllanes ; Jeremy T Blitzer ; Craig Logsdon ; Daniel Rakiec ; David Ruddy ; Terry Hyslop ; Allison Hall ; Jeffrey R Marks ; Gregory E Crawford ; Myles Brown ; Donald P McdonnellSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensThe estrogen receptor (ER) is expressed in the majority of luminal breast cancers and inhibition of its transcriptional activity with selective estrogen receptor modulators, selective estrogen rec...
Source: GEO: Gene Expression Omnibus - December 16, 2017 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research

GSE113092 GRHL2 is a key lineage determining factor which collaborates with FOXA1 to establish a targetable collateral pathway in the setting of endocrine therapy-resistant breast cancer ChIP-seq
Contributors : Jeff S Jasper ; Kimberly J Cocce ; Logan Everett ; Suzanne Wardell ; Thomas Westerling ; Taylor Krebs ; Robert Baldi ; Tricia M Wright ; Alex Yllanes ; Jeremy T Blitzer ; Craig Logsdon ; Daniel Rakiec ; David Ruddy ; Terry Hyslop ; Allison Hall ; Jeffrey R Marks ; Gregory E Crawford ; Myles Brown ; Donald P McdonnellSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensThe estrogen receptor (ER) is expressed in the majority of luminal breast cancers and inhibition of its transcriptional activity with selective estrogen receptor modulators, selective estrogen rec...
Source: GEO: Gene Expression Omnibus - April 13, 2018 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research

JMJD6 orchestrates a transcriptional program in favor of endocrine resistance in ER+ breast cancer cells
High expression of Jumonji domain containing protein 6 (JMJD6) is strongly associated with poor prognosis in estrogen receptor positive (ER+) breast cancer. We overexpressed JMJD6 in MCF7 cells (JOE cells) and performed RNA-seq analysis. 76% of differentially expressed genes (DEGs) overlapped with ER target genes. Pathway analysis revealed that JMJD6 upregulated a larger subset of genes related to cell proliferation as compared to ER. Interestingly, JOE cells showed a decrease in ER target gene expression prompting us to check ER levels. Indeed, JOE cells showed a significant decrease in both ESR1 and ER levels and JMJD6 s...
Source: Frontiers in Endocrinology - November 7, 2022 Category: Endocrinology Source Type: research

p53 inactivation decreases dependence on estrogen/ERK signalling for proliferation but promotes EMT and susceptility to 3-bromopyruvate in ERα+ breast cancer MCF-7 cells.
Conclusions.- a) ERα(+) breast cancer cells dysfunctional for TP53 which proliferate irrespective of low estrogen and chemical MEK inhibition are likely to increase metabolic consumption becoming increasingly susceptible to 3-BrPA; b) targeting the pyruvate pathway may improve response to endocrine therapy in ERα(+) breast cancer with p53 dysfunction. PMID: 24486524 [PubMed - as supplied by publisher]
Source: Biochemical Pharmacology - January 28, 2014 Category: Drugs & Pharmacology Authors: Rieber M, Strasberg-Rieber M Tags: Biochem Pharmacol Source Type: research